BeOne Medicines Ltd. (NASDAQ:ONC) ranks ninth on the list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. The company, formerly BeiGene, relocated to Switzerland in May 2025, expanding its global presence in oncology with 50+ investigational assets and operations in 45+ countries.

A significant accomplishment for BeOne Medicines Ltd. (NASDAQ:ONC) was obtaining European Commission approval for Tevimbra (tislelizumab) to treat various cancers, solidifying its position in immuno-oncology. The drug has already received FDA approval for esophageal cancer, with ongoing regulatory progress anticipated.

At the 2025 EHA Congress, BeOne Medicines Ltd. showcased advancements in hematology with Sonrotoclax and BGB-16673 showing promise in treating CLL and MCL. BRUKINSA (zanubrutinib) continues to deliver superior outcomes, while the company progresses toward Phase 3 trials for its innovative therapies.

BeOne Medicines Ltd. (NASDAQ:ONC) expanded its pipeline with 13 new molecules entering clinical trials in 2024, totaling 170+ global trials and 25,000+ patients enrolled. A recent licensing agreement with Neowise Biotechnology enhances the company’s focus on next-gen cell therapies, particularly TCR-based platforms.

Read more at Yahoo Finance: BeOne Medicines Ltd. (ONC) Wins EU Nod for Tevimbra